大麻二醇修改了患者和患有的老鼠的大脑组织中的谷氨酸过度释放:试点研究
Christopher Martínez-Aguirre1, Luis Alfredo Márquez1, Cindy Lizbeth Santiago-Castañeda1
1Pharmacobiology Department, Center for Research and Advanced Studies, Mexico City 14330, Mexico.
Biomedicines
|December 23, 2023
概括
大麻 (CBD) 可以降低某些患有耐药性 (DRE) 的患者的谷氨酸过度释放. 然而,一些患者对CBD治疗没有反应,这凸显了对生物标志物的需求,以指导DRE治疗.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 的研究研究.
背景情况:
- 耐药性 (DRE) 的特征是细胞外谷氨酸水平升高.
- 卡纳比 (CBD) 假设可以减轻谷氨酸过度释放.
研究的目的:
- 研究CBD是否能减少人类DRE皮质突触体和临床前模型中引起的谷氨酸释放.
- 为了确定对CBD对谷氨酸释放的影响有反应或无反应的患者子组.
主要方法:
- 来自耐药叶 (DR-TLE) 和外叶 (DR-ETLE) 患者的突触体被用来测量KCl引起的谷氨酸释放,其CBD度不同.
- 电生理学记录在人类性新皮质样本中评估了神经元活力.
- 为了评估海马谷氨酸水平,CBD被分慢性地给了和皮洛卡尔宾诱导的,以评估海马谷氨酸水平.
主要成果:
- 低CBD度 (<100μM) 减少了响应DRE患者 (n=14) 的突触体中的谷氨酸释放.
- 一小部分患者 (n=6) 尽管暴露于CBD,但谷氨酸释放量没有减少.
- 电生理学证实了所有人类样本中的神经元活力.
- 在大鼠中,亚慢性CBD给药降低了海马谷氨酸的过度释放.
结论:
- 急性,低剂量的CBD可以减少部分DRE患者的谷氨酸过度释放.
- 在临床前模型中,亚慢性CBD的使用有效.
- 确定CBD响应性的生物标志物对于优化DRE治疗至关重要.
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
412
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
412
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
307
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
307
01:24Arteries of the Lower Limbs
191
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
191
01:20Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
01:17Antiepileptic Drugs: Calcium Channel Blockers
410
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
410